Cantor Fitzgerald Cuts PT on Apellis Pharmaceuticals (APLS) to $31 From $35 – Here’s Why

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) is one of the best high growth healthcare stocks to buy now. Cantor Fitzgerald cut the price target on Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) to $31 from $35 on March 13, reiterating an Overweight rating on the shares and telling investors in a research note that it updated its model after the fiscal Q4 earnings report, which includes pruning estimates for both Syfovre and Empaveli.

Why Apellis Pharmaceuticals, Inc. (APLS) Skyrocketed On Monday

In its fiscal Q4 and full year 2025 financial results, Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) reported net product revenues of $689 million for the full year 2025, with SYFOVRE® (pegcetacoplan injection) full year 2025 net product revenue of $587 million and EMPAVELI® (pegcetacoplan) full year 2025 net product revenue of $102 million. It also stated that the regulatory submission for SYFOVRE prefilled syringe is planned for the first half of 2026. Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) has cash and cash equivalents of $466 million as of December 31, 2025, with projected revenues, cash, and cash equivalents anticipated to be sufficient to fund operations to profitability.

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) is a commercial-stage biopharmaceutical company that discovers, develops, and commercializes novel therapeutic compounds for treating diseases with unmet needs. Its product portfolio primarily includes EMPAVELI and SYFOVRE. SYFOVRE treats geographic atrophy secondary to age-related macular degeneration (GA), while EMPAVELI treats paroxysmal nocturnal hemoglobinuria (PNH).

While we acknowledge the risk and potential of APLS as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than APLS and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 15 Stocks That Will Make You Rich in 10 Years AND 12 Best Stocks That Will Always Grow.

Disclosure: None. Follow Insider Monkey on Google News.